Cover Story
Conversation with The Cancer LetterRegulatory News
By Matthew Bin Han Ong and Paul Goldberg
When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- Trump 2016: A look back at the 45th president’s impact on oncology
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt - Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes
- A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline